Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

unknown125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

NCT04094090
completedphase_1

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
completedphase_1

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04177082
unknownphase_1

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865

Clinical Trials (4)

Showing 4 of 4 trials
NCT04094090Phase 2

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

Recruiting
NCT04667572Phase 1

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Completed
NCT04177082Phase 1

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Completed
NCT04401865Phase 1

Safety and Effectiveness of the PXL-Platinum 330 System

Unknown

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4